{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:49:02Z","timestamp":1790938142924,"version":"4.1.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>State-of-the-art response assessment of central nervous system lymphoma (CNSL) by magnetic resonance imaging is challenging and an insufficient predictor of treatment outcomes. Accordingly, the development of novel risk stratification strategies in CNSL is a high unmet medical need. We applied ultrasensitive circulating tumor DNA (ctDNA) sequencing to 146 plasma and cerebrospinal fluid (CSF) samples from 67 patients, aiming to develop an entirely noninvasive dynamic risk model considering clinical and molecular features of CNSL. Our ultrasensitive method allowed for the detection of CNSL-derived mutations in plasma ctDNA with high concordance to CSF and tumor tissue. Undetectable plasma ctDNA at baseline was associated with favorable outcomes. We tracked tumor-specific mutations in plasma-derived ctDNA over time and developed a novel CNSL biomarker based on this information: peripheral residual disease (PRD). Persistence of PRD after treatment was highly predictive of relapse. Integrating established baseline clinical risk factors with assessment of radiographic response and PRD during treatment resulted in the development and independent validation of a novel tool for risk stratification: molecular prognostic index for CNSL (MOP-C). MOP-C proved to be highly predictive of outcomes in patients with CNSL (failure-free survival hazard ratio per risk group of 6.60; 95% confidence interval, 3.12-13.97; P\u00a0&amp;lt; .0001) and is publicly available at www.mop-c.com. Our results highlight the role of ctDNA sequencing in CNSL. MOP-C has the potential to improve the current standard of clinical risk stratification and radiographic response assessment in patients with CNSL, ultimately paving the way toward individualized treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023022020","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T04:14:50Z","timestamp":1699589690000},"page":"522-534","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-8504","authenticated-orcid":false,"given":"Jan-Michel","family":"Heger","sequence":"first","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen (CCCE), Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7048-0351","authenticated-orcid":false,"given":"Julia","family":"Mattlener","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen (CCCE), Cologne, Germany"},{"name":"4German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7163-819X","authenticated-orcid":false,"given":"Jessica","family":"Schneider","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen (CCCE), Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7887-8313","authenticated-orcid":false,"given":"Philipp","family":"G\u00f6del","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00eblle","family":"Sieg","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen (CCCE), Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5033-2201","authenticated-orcid":false,"given":"Fabian","family":"Ullrich","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (Deutsches Konsortium f\u00fcr Translationale Krebsforschung partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany"},{"name":"6CCCE, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2404-6703","authenticated-orcid":false,"given":"Richard","family":"Lewis","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen (CCCE), Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Bucaciuc-Mracica","sequence":"additional","affiliation":[{"name":"7Institute for Computational Cancer Biology, Center for Integrated Oncology, Cancer Research Center Cologne Essen, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9155-4268","authenticated-orcid":false,"given":"Roland F.","family":"Schwarz","sequence":"additional","affiliation":[{"name":"7Institute for Computational Cancer Biology, Center for Integrated Oncology, Cancer Research Center Cologne Essen, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany"},{"name":"8Berlin Institute for the Foundations of Learning and Data, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1811-5132","authenticated-orcid":false,"given":"Daniel","family":"Rue\u00df","sequence":"additional","affiliation":[{"name":"9Department of Stereotaxy and Functional Neurosurgery, Center of Neurosurgery, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0466-6646","authenticated-orcid":false,"given":"Maximilian I.","family":"Ruge","sequence":"additional","affiliation":[{"name":"9Department of Stereotaxy and Functional Neurosurgery, Center of Neurosurgery, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4724-5526","authenticated-orcid":false,"given":"Manuel","family":"Montesinos-Rongen","sequence":"additional","affiliation":[{"name":"10Institute of Neuropathology, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Deckert","sequence":"additional","affiliation":[{"name":"10Institute of Neuropathology, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Blau","sequence":"additional","affiliation":[{"name":"11Institute of Neuropathology, University of Duisburg-Essen, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9559-8575","authenticated-orcid":false,"given":"Nadine","family":"Kutsch","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen (CCCE), Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyatt","family":"Balke-Want","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen (CCCE), Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"},{"name":"12Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Weiss","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7897-7181","authenticated-orcid":false,"given":"Kerstin","family":"Becker","sequence":"additional","affiliation":[{"name":"13West German Genome Center, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Christian","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (Deutsches Konsortium f\u00fcr Translationale Krebsforschung partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany"},{"name":"6CCCE, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen (CCCE), Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"4German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-4487","authenticated-orcid":false,"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"4German Hodgkin Study Group, Cologne, Germany"},{"name":"6CCCE, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Borchmann","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen (CCCE), Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"},{"name":"4German Hodgkin Study Group, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"suppl 1","key":"2024020816243026800_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/hon.3148","article-title":"Management of primary and secondary CNS lymphoma","volume":"41","author":"Khwaja","year":"2023","journal-title":"Hematol Oncol"},{"issue":"9","key":"2024020816243026800_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024020816243026800_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2024020816243026800_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bjh.18539","article-title":"Management of secondary central nervous system lymphoma","volume":"200","author":"Cwynarski","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"2024020816243026800_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3324\/haematol.2022.281457","article-title":"Prevention and management of secondary central nervous system lymphoma","volume":"108","author":"Bobillo","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"2024020816243026800_bib6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/JCO.1992.10.4.635","article-title":"Combined modality therapy for primary CNS lymphoma","volume":"10","author":"DeAngelis","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2024020816243026800_bib7","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","article-title":"Treatment for primary CNS lymphoma: the next step","volume":"18","author":"Abrey","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2024020816243026800_bib8","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2003.11.036","article-title":"Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group","volume":"21","author":"Hoang-Xuan","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024020816243026800_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Hoang-Xuan","year":"2023","journal-title":"Neuro Oncol"},{"issue":"7","key":"2024020816243026800_bib10","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"23","author":"Barajas","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"2024020816243026800_bib11","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024020816243026800_bib12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/leu.2016.334","article-title":"High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)","volume":"31","author":"Fritsch","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"2024020816243026800_bib13","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an International Workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024020816243026800_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/ejh.13639","article-title":"Treatment patterns and disease course of previously untreated primary central nervous system lymphoma: feasibility of MTX-based regimens in clinical routine","volume":"107","author":"Sieg","year":"2021","journal-title":"Eur J Haematol"},{"issue":"6","key":"2024020816243026800_bib15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00401-011-0891-2","article-title":"Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma","volume":"122","author":"Montesinos-Rongen","year":"2011","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2024020816243026800_bib16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00401-012-1064-7","article-title":"Genes regulating the B cell receptor pathway are recurrently mutated\u00a0in\u00a0primary central nervous system lymphoma","volume":"124","author":"Montesinos-Rongen","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2024020816243026800_bib17","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-05-1465","article-title":"Primary diffuse large B-cell lymphomas of the central nervous system\u00a0are targeted by aberrant somatic hypermutation","volume":"103","author":"Montesinos-Rongen","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2024020816243026800_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/leu.2014.264","article-title":"The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing","volume":"29","author":"Vater","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2024020816243026800_bib19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"2024020816243026800_bib20","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024020816243026800_bib21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A\u00a0probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"2024020816243026800_bib22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"2024020816243026800_bib23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"24","key":"2024020816243026800_bib24","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"6769","key":"2024020816243026800_bib25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"364","key":"2024020816243026800_bib26","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"3","key":"2024020816243026800_bib27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell"},{"issue":"10","key":"2024020816243026800_bib28","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jmoldx.2020.07.002","article-title":"Analysis of driver mutational hot spots in blood-derived cell-free DNA of patients with primary central nervous system lymphoma obtained before intracerebral biopsy","volume":"22","author":"Montesinos-Rongen","year":"2020","journal-title":"J\u00a0Mol Diagn"},{"issue":"29","key":"2024020816243026800_bib29","doi-asserted-by":"crossref","first-page":"48157","DOI":"10.18632\/oncotarget.18325","article-title":"Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma","volume":"8","author":"Fontanilles","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"2024020816243026800_bib30","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/bjh.15674","article-title":"MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma","volume":"185","author":"Hiemcke-Jiwa","year":"2019","journal-title":"Br J Haematol"},{"issue":"23","key":"2024020816243026800_bib31","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1200\/JCO.20.02573","article-title":"Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma","volume":"39","author":"Alig","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024020816243026800_bib32","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024020816243026800_bib33","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2024020816243026800_bib34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"28","key":"2024020816243026800_bib35","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024020816243026800_bib36","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024020816243026800_bib37","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease\u00a0detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"issue":"2","key":"2024020816243026800_bib38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 2","key":"2024020816243026800_bib39","article-title":"Effects on survival of non-myeloablative chemoimmunotherapy compared to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) as consolidation therapy in patients with primary CNS lymphoma - results of an international randomized phase III trial (MATRix\/IELSG43)","volume":"140","author":"Illerhaus","year":"2022","journal-title":"Blood"},{"key":"2024020816243026800_bib40","unstructured":"Wang\n              C\n            , WuQ, WeimerM, . FLAML: a fast and lightweight AutoML library. arXiv. Preprint posted online 19 May 2021. http:\/\/doi.org\/10.48550\/arXiv.1911.04706."},{"key":"2024020816243026800_bib41","year":"2020"},{"issue":"2","key":"2024020816243026800_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.annonc.2022.11.002","article-title":"Molecular and clinical diversity in primary central nervous system lymphoma","volume":"34","author":"Hern\u00e1ndez-Verdin","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"2024020816243026800_bib43","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","article-title":"The genomic and transcriptional landscape of primary central nervous system lymphoma","volume":"13","author":"Radke","year":"2022","journal-title":"Nat Commun"},{"issue":"24","key":"2024020816243026800_bib44","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.3390\/cancers13246334","article-title":"Impact of a faulty germinal center reaction on the pathogenesis of primary diffuse large B cell lymphoma of the central nervous system","volume":"13","author":"Montesinos-Rongen","year":"2021","journal-title":"Cancers"},{"issue":"19","key":"2024020816243026800_bib45","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","article-title":"Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas","volume":"18","author":"Gonzalez-Aguilar","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2024020816243026800_bib46","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.18632\/oncotarget.2080","article-title":"Mutational analysis of primary central nervous system lymphoma","volume":"5","author":"Bruno","year":"2014","journal-title":"Oncotarget"},{"issue":"17","key":"2024020816243026800_bib47","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas","volume":"21","author":"Braggio","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2024020816243026800_bib48","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.3109\/10428194.2014.979413","article-title":"Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations","volume":"56","author":"Yamada","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2024020816243026800_bib49","doi-asserted-by":"crossref","first-page":"878618","DOI":"10.3389\/fgene.2022.878618","article-title":"Whole-genome\/exome sequencing uncovers mutations and copy number variations in primary diffuse large B-cell lymphoma of the central nervous system","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Genet"},{"issue":"7","key":"2024020816243026800_bib50","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/NEN.0b013e31817dd02d","article-title":"Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma","volume":"67","author":"Courts","year":"2008","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"4","key":"2024020816243026800_bib51","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00401-010-0709-7","article-title":"Mutations of CARD11 but not TNFAIP3 may activate the NF-\u03baB pathway in primary CNS lymphoma","volume":"120","author":"Montesinos-Rongen","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2024020816243026800_bib52","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3324\/haematol.2019.241208","article-title":"Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas","volume":"106","author":"Bobillo","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2024020816243026800_bib53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40478-019-0692-8","article-title":"Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis","volume":"7","author":"Rimelen","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"2024020816243026800_bib54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/cas.13450","article-title":"Clinical significance of disease-specific MYD88 mutations in circulating DNA in\u00a0primary central nervous system lymphoma","volume":"109","author":"Hattori","year":"2018","journal-title":"Cancer Sci"},{"issue":"12","key":"2024020816243026800_bib55","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood"},{"issue":"7920","key":"2024020816243026800_bib56","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41586-022-04906-8","article-title":"Super-enhancer hypermutation alters oncogene expression in B cell lymphoma","volume":"607","author":"Bal","year":"2022","journal-title":"Nature"},{"issue":"1","key":"2024020816243026800_bib57","first-page":"210","article-title":"Determinants of resistance to engineered\u00a0T\u00a0cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer\u00a0Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023022020\/2211250\/blood_bld-2023-022020-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023022020\/2211250\/blood_bld-2023-022020-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T16:26:51Z","timestamp":1707409611000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/6\/522\/498659\/Entirely-noninvasive-outcome-prediction-in-central"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,2,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022020","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]}}}